{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  St John's wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"acebutolol\" outputclass=\"int-drug\">acebutolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  acebutolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acebutolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"acrivastine\" outputclass=\"int-drug\">acrivastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   acrivastine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acrivastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"adrenaline/epinephrine\" outputclass=\"int-drug\">Adrenaline/epinephrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Adrenaline/epinephrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adrenaline/epinephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  alcohol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alfentanil\" outputclass=\"int-drug\">Alfentanil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alfentanil   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"alfuzosin\" outputclass=\"int-drug\">alfuzosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  alfuzosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfuzosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"alimemazine\" outputclass=\"int-drug\">alimemazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   alimemazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alimemazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  aliskiren  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  alprostadil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  amantadine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amantadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  amitriptyline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026325_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">Amitriptyline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Amitriptyline   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"amlodipine\" outputclass=\"int-drug\">amlodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  amlodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amlodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"antazoline\" outputclass=\"int-drug\">antazoline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   antazoline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antazoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  apomorphine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  apraclonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  aripiprazole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  asenapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"atenolol\" outputclass=\"int-drug\">atenolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  atenolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"atomoxetine\" outputclass=\"int-drug\">atomoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 2 weeks after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of adverse effects when given with   atomoxetine .  Manufacturer advises avoid and for 2 weeks after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atomoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"avanafil\" outputclass=\"int-drug\">avanafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  avanafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Avanafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"azelastine\" outputclass=\"int-drug\">azelastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   azelastine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azelastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  azilsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  baclofen  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">bambuterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   bambuterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  bendroflumethiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  benperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"betaxolol\" outputclass=\"int-drug\">betaxolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  betaxolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betaxolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"bilastine\" outputclass=\"int-drug\">bilastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   bilastine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bilastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"bisoprolol\" outputclass=\"int-drug\">bisoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  bisoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bisoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  bortezomib  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  brimonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  bromocriptine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromocriptine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"buclizine\" outputclass=\"int-drug\">buclizine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   buclizine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  bumetanide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"buprenorphine\" outputclass=\"int-drug\">Buprenorphine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Buprenorphine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buprenorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">enhance</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">MHRA advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bupropion   might   enhance   the risk of serotonin syndrome when given with   tranylcypromine .  MHRA advises monitor .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026350_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe hypertension when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bupropion   is predicted to   increase   the risk of severe hypertension when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"buspirone\" outputclass=\"int-drug\">Buspirone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of elevated blood pressure when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Buspirone   is predicted to   increase   the risk of elevated blood pressure when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  cabergoline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabergoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  canagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  candesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  captopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  cariprazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"carvedilol\" outputclass=\"int-drug\">carvedilol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  carvedilol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carvedilol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"celiprolol\" outputclass=\"int-drug\">celiprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  celiprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celiprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"cetirizine\" outputclass=\"int-drug\">cetirizine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   cetirizine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cetirizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  chlorothiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"chlorphenamine\" outputclass=\"int-drug\">chlorphenamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   chlorphenamine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorphenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  chlorpromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026363_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   chlorpromazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  chlortalidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"cinnarizine\" outputclass=\"int-drug\">cinnarizine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   cinnarizine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinnarizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"clemastine\" outputclass=\"int-drug\">clemastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   clemastine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clemastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  clomipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026368_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tranylcypromine  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026368_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  clonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  clozapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"codeine\" outputclass=\"int-drug\">Codeine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Codeine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Codeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"cyclizine\" outputclass=\"int-drug\">cyclizine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   cyclizine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">cyproheptadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   cyproheptadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  dapagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  desflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"desloratadine\" outputclass=\"int-drug\">desloratadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   desloratadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desloratadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026378_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">Dexamfetamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dexamfetamine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diamorphine\" outputclass=\"int-drug\">Diamorphine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diamorphine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diamorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"diazoxide\" outputclass=\"int-drug\">diazoxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  diazoxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dihydrocodeine\" outputclass=\"int-drug\">Dihydrocodeine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dihydrocodeine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dihydrocodeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">diltiazem</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  diltiazem  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"diphenoxylate\" outputclass=\"int-drug\">Diphenoxylate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Diphenoxylate   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diphenoxylate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dipipanone\" outputclass=\"int-drug\">Dipipanone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dipipanone   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipipanone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  dipyridamole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dobutamine\" outputclass=\"int-drug\">Dobutamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dobutamine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dobutamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dopamine\" outputclass=\"int-drug\">Dopamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dopamine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dopamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  dosulepin  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026388_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">Dosulepin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dosulepin   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"doxapram\" outputclass=\"int-drug\">doxapram</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the effects of   doxapram .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxapram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"doxazosin\" outputclass=\"int-drug\">doxazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  doxazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  doxepin  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026391_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"doxepin\" outputclass=\"int-drug\">Doxepin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Doxepin   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"doxylamine\" outputclass=\"int-drug\">doxylamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   doxylamine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxylamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  droperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  empagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  enalapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"entacapone\" outputclass=\"int-drug\">Entacapone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of elevated blood pressure when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Entacapone   is predicted to   increase   the risk of elevated blood pressure when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Entacapone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ephedrine\" outputclass=\"int-drug\">Ephedrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ephedrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ephedrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  eplerenone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  epoprostenol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  eprosartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  ertugliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  esketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"esmolol\" outputclass=\"int-drug\">esmolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  esmolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esmolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  etomidate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"felodipine\" outputclass=\"int-drug\">felodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  felodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">fenfluramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  fenfluramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026410_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">Fentanyl</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fentanyl   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   fexofenadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fexofenadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  flupentixol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"formoterol\" outputclass=\"int-drug\">formoterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   formoterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">fosinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  fosinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  furosemide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"glyceryl trinitrate\" outputclass=\"int-drug\">glyceryl trinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  glyceryl trinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glyceryl trinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  guanfacine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  haloperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"hydralazine\" outputclass=\"int-drug\">hydralazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  hydralazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydralazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  hydrochlorothiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  hydroflumethiazide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydromorphone\" outputclass=\"int-drug\">Hydromorphone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydromorphone   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydromorphone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   hydroxyzine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  iloprost  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  imidapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  imipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026430_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tranylcypromine  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026430_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imipramine\" outputclass=\"int-drug\">Imipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Imipramine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">indacaterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   indacaterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  indapamide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  indoramin  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026433_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the effects of   indoramin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indoramin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  irbesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  isoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"isometheptene\" outputclass=\"int-drug\">Isometheptene</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Isometheptene   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isometheptene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"isosorbide dinitrate\" outputclass=\"int-drug\">isosorbide dinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  isosorbide dinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide dinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"isosorbide mononitrate\" outputclass=\"int-drug\">isosorbide mononitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  isosorbide mononitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide mononitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  ketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"ketotifen\" outputclass=\"int-drug\">ketotifen</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   ketotifen .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"labetalol\" outputclass=\"int-drug\">labetalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  labetalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Labetalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lacidipine\" outputclass=\"int-drug\">lacidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lacidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lacidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lercanidipine\" outputclass=\"int-drug\">lercanidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lercanidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lercanidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"levobunolol\" outputclass=\"int-drug\">levobunolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  levobunolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobunolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"levocetirizine\" outputclass=\"int-drug\">levocetirizine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   levocetirizine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levocetirizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  levodopa  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026446_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"levodopa\" outputclass=\"int-drug\">Levodopa</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Levodopa   increases   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levodopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  levomepromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026447_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   levomepromazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026448_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of adverse effects when given with   linezolid .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026449_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">Lisdexamfetamine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Lisdexamfetamine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lisinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lofepramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026452_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">Lofepramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Lofepramine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lofexidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"loratadine\" outputclass=\"int-drug\">loratadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   loratadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loratadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  losartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  loxapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  lurasidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"meptazinol\" outputclass=\"int-drug\">Meptazinol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Meptazinol   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meptazinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metaraminol\" outputclass=\"int-drug\">Metaraminol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metaraminol   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metaraminol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026460_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methadone\" outputclass=\"int-drug\">Methadone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Methadone   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  methoxyflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">methyldopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  methyldopa  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026462_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">alter</ph> <ph outputclass=\"int-parameter\">the antihypertensive effects of</ph> <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">methyldopa</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   alter   the antihypertensive effects of   methyldopa .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methyldopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylphenidate\" outputclass=\"int-drug\">Methylphenidate</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylphenidate   causes   a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylphenidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  metolazone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  metoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mianserin\" outputclass=\"int-drug\">Mianserin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mianserin   is predicted to   increase   the risk of toxicity when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"midodrine\" outputclass=\"int-drug\">Midodrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Midodrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midodrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"minoxidil\" outputclass=\"int-drug\">minoxidil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  minoxidil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minoxidil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">mizolastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   mizolastine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"morphine\" outputclass=\"int-drug\">Morphine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Morphine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Morphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"moxisylyte\" outputclass=\"int-drug\">moxisylyte</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  moxisylyte  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxisylyte</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  moxonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nadolol\" outputclass=\"int-drug\">nadolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nadolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nadolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nebivolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nefopam\" outputclass=\"int-drug\">Nefopam</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of serious elevations in blood pressure when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nefopam   is predicted to   increase   the risk of serious elevations in blood pressure when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nefopam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nicardipine\" outputclass=\"int-drug\">nicardipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nicardipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicardipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">nicorandil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nicorandil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nifedipine\" outputclass=\"int-drug\">nifedipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nifedipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nifedipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nimodipine\" outputclass=\"int-drug\">nimodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nimodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nimodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nitroprusside\" outputclass=\"int-drug\">nitroprusside</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nitroprusside  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitroprusside</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nitrous oxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"noradrenaline/norepinephrine\" outputclass=\"int-drug\">Noradrenaline/norepinephrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Noradrenaline/norepinephrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Noradrenaline/norepinephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  nortriptyline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026487_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">Nortriptyline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Nortriptyline   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  olanzapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  olmesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">olodaterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   olodaterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"opicapone\" outputclass=\"int-drug\">Opicapone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of elevated blood pressure when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Opicapone   is predicted to   increase   the risk of elevated blood pressure when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Opicapone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxycodone\" outputclass=\"int-drug\">Oxycodone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxycodone   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxycodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">Ozanimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ozanimod   might   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  paliperidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026498_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">Pentazocine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Pentazocine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pericyazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026499_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   pericyazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  perindopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026501_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pethidine\" outputclass=\"int-drug\">Pethidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Pethidine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   increase   the effects of   tranylcypromine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenylephrine\" outputclass=\"int-drug\">Phenylephrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenylephrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenylephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pholcodine\" outputclass=\"int-drug\">Pholcodine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pholcodine   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pholcodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pimozide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pindolol\" outputclass=\"int-drug\">pindolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pindolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pindolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"pizotifen\" outputclass=\"int-drug\">pizotifen</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   pizotifen .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pizotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  pramipexole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"prazosin\" outputclass=\"int-drug\">prazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  prazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   increase   the effects of   tranylcypromine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  prochlorperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026511_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   prochlorperazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  promazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026512_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   promazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"promethazine\" outputclass=\"int-drug\">promethazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   promethazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promethazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  propofol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  propranolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pseudoephedrine\" outputclass=\"int-drug\">Pseudoephedrine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pseudoephedrine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pseudoephedrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  quetiapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"quinagolide\" outputclass=\"int-drug\">quinagolide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  quinagolide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinagolide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  quinapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  ramipril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026521_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">Rasagiline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Rasagiline   is predicted to   increase   the risk of adverse effects when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"reboxetine\" outputclass=\"int-drug\">Reboxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Reboxetine   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Reboxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"remifentanil\" outputclass=\"int-drug\">Remifentanil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Remifentanil   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remifentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"riociguat\" outputclass=\"int-drug\">riociguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  riociguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Riociguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  risperidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026526_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the exposure to   rizatriptan .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  ropinirole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropinirole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"rotigotine\" outputclass=\"int-drug\">rotigotine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  rotigotine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotigotine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of antimuscarinic adverse effects when given with</ph> <ph otherprops=\"rupatadine\" outputclass=\"int-drug\">rupatadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of antimuscarinic adverse effects when given with   rupatadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rupatadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sacubitril\" outputclass=\"int-drug\">sacubitril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sacubitril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sacubitril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026531_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"safinamide\" outputclass=\"int-drug\">Safinamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 1 week after stopping <ph otherprops=\"safinamide\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/safinamide.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP213016\">safinamide</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Safinamide   is predicted to   increase   the risk of adverse effects when given with   tranylcypromine .  Manufacturer advises avoid and for 1 week after stopping  safinamide .    \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">salbutamol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   salbutamol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">salmeterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   salmeterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sapropterin\" outputclass=\"int-drug\">sapropterin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sapropterin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sapropterin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  selegiline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026535_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  tranylcypromine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026535_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"selegiline\" outputclass=\"int-drug\">Selegiline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Selegiline   is predicted to   increase   the risk of adverse effects when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sevoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sildenafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sodium oxybate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"solriamfetol\" outputclass=\"int-drug\">Solriamfetol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Solriamfetol   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Solriamfetol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sotalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  spironolactone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sulpiride  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026544_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the exposure to   sumatriptan .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"tadalafil\" outputclass=\"int-drug\">tadalafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  tadalafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tadalafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  tamsulosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamsulosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">Tapentadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tapentadol   is predicted to   increase   the risk of serotonin syndrome when given with   tranylcypromine .  Manufacturer advises caution .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026547_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">Tapentadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tapentadol   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  telmisartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"terazosin\" outputclass=\"int-drug\">terazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  terazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">terbutaline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   terbutaline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">Tetrabenazine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation and hypertension when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetrabenazine   potentially   increases   the risk of CNS excitation and hypertension when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  thiopental  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "240",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"timolol\" outputclass=\"int-drug\">timolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  timolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "241",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Timolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  tizanidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "242",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tolcapone\" outputclass=\"int-drug\">Tolcapone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tolcapone   is predicted to   increase   the effects of   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "243",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolcapone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  torasemide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "244",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026557_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tramadol\" outputclass=\"int-drug\">Tramadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of CNS excitation or depression when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tramadol   is predicted to   increase   the risk of CNS excitation or depression when given with   tranylcypromine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "245",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  trandolapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "246",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "247",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  treprostinil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "248",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  trifluoperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026561_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neuroleptic malignant syndrome when given with</ph> <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of neuroleptic malignant syndrome when given with   trifluoperazine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "249",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  trimipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026562_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">Trimipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Trimipramine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "250",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026563_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">Tryptophan</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tryptophan   increases   the risk of adverse effects when given with   tranylcypromine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "251",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  valsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "252",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  vardenafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "253",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "254",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"verapamil\" outputclass=\"int-drug\">verapamil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  verapamil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "255",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"vericiguat\" outputclass=\"int-drug\">vericiguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  vericiguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "256",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vericiguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  vernakalant  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "257",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vernakalant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular adverse effects when given with</ph> <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">vilanterol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the risk of cardiovascular adverse effects when given with   vilanterol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "258",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "259",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  xipamide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "260",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xylometazoline\" outputclass=\"int-drug\">Xylometazoline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of a hypertensive crisis when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xylometazoline   is predicted to   increase   the risk of a hypertensive crisis when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "261",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xylometazoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026574_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">Tranylcypromine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tranylcypromine   is predicted to   increase   the exposure to   zolmitriptan .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "262",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2#bnf_i1643858026575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tranylcypromine\" outputclass=\"int-heading-drug\">tranylcypromine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tranylcypromine  and  zuclopenthixol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "263",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Tranylcypromine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/tranylcypromine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Tranylcypromine </title>"
			},
			"rdfs:label": "tranylcypromine"
		}
	]
}